BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25310817)

  • 1. The utility of gadoxetic acid-enhanced MR imaging to characterize atypical cirrhotic nodules detected on dynamic CT images.
    Chou CT; Wu WP; Chen CB; Su WW; Chen RC; Chen YL
    PLoS One; 2014; 9(10):e107869. PubMed ID: 25310817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images.
    Wang YC; Chou CT; Lin CP; Chen YL; Chen YF; Chen RC
    PLoS One; 2017; 12(3):e0174594. PubMed ID: 28355258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article.
    Shin SK; Kim YS; Choi SJ; Shim YS; Jung DH; Kwon OS; Choi DJ; Kim JH
    Medicine (Baltimore); 2017 Jul; 96(29):e7278. PubMed ID: 28723741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MR features of regenerative nodules and dysplastic nodules in the cirrhotic liver.
    Xu H; Kong X; Xiong Y; Zhang X
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(5):601-3. PubMed ID: 16463687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of gadoxetic acid-enhanced and diffusion-weighted MR imaging in evaluation of hepatocellular carcinomas with atypical enhancement pattern on contrast-enhanced multiphasic MDCT in patients with chronic liver disease.
    Kim HS; Kim SH; Kang TW; Song KD; Choi D; Park CK
    Eur J Radiol; 2015 Apr; 84(4):555-62. PubMed ID: 25617950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration.
    Golfieri R; Grazioli L; Orlando E; Dormi A; Lucidi V; Corcioni B; Dettori E; Romanini L; Renzulli M
    J Magn Reson Imaging; 2012 Sep; 36(3):648-57. PubMed ID: 22592930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT.
    Inoue T; Kudo M; Komuta M; Hayaishi S; Ueda T; Takita M; Kitai S; Hatanaka K; Yada N; Hagiwara S; Chung H; Sakurai T; Ueshima K; Sakamoto M; Maenishi O; Hyodo T; Okada M; Kumano S; Murakami T
    J Gastroenterol; 2012 Sep; 47(9):1036-47. PubMed ID: 22526270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
    Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
    AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase.
    Saito K; Kotake F; Ito N; Ozuki T; Mikami R; Abe K; Shimazaki Y
    Magn Reson Med Sci; 2005; 4(1):1-9. PubMed ID: 16127248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging.
    Chou CT; Chou JM; Chang TA; Huang SF; Chen CB; Chen YL; Chen RC
    World J Gastroenterol; 2013 Nov; 19(42):7433-9. PubMed ID: 24259975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study.
    Granito A; Galassi M; Piscaglia F; Romanini L; Lucidi V; Renzulli M; Borghi A; Grazioli L; Golfieri R; Bolondi L
    Aliment Pharmacol Ther; 2013 Feb; 37(3):355-63. PubMed ID: 23199022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT.
    Park VY; Choi JY; Chung YE; Kim H; Park MS; Lim JS; Kim KW; Kim MJ
    Liver Int; 2014 Nov; 34(10):1593-602. PubMed ID: 24673802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.
    Phongkitkarun S; Limsamutpetch K; Tannaphai P; Jatchavala J
    World J Gastroenterol; 2013 Dec; 19(45):8357-65. PubMed ID: 24363528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis.
    Ayuso C; Forner A; Darnell A; Rimola J; García-Criado Á; Bianchi L; Vilana R; Oliveira R; Llarch N; Bruix J
    Liver Int; 2019 Jul; 39(7):1281-1291. PubMed ID: 31077539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging.
    Sano K; Ichikawa T; Motosugi U; Sou H; Muhi AM; Matsuda M; Nakano M; Sakamoto M; Nakazawa T; Asakawa M; Fujii H; Kitamura T; Enomoto N; Araki T
    Radiology; 2011 Dec; 261(3):834-44. PubMed ID: 21998047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.